$BRNS
Barinthus Biotherapeutics PLC Stock $brns

$brns Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000182818524000085 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$14.97M	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$13.42M	$961.0K
YoY Change		1296.46%	-108.63%
% of Gross Profit
Research & Development		$11.14M	$15.14M
YoY Change		-26.45%	55.42%
% of Gross Profit
Depreciation & Amortization		$700.0K	$700.0K
YoY Change		0.0%	-41.08%
% of Gross Profit
Operating Expenses		$24.56M	$16.11M
YoY Change		52.49%	-1260.3%
Operating Profit		-$9.380M	-$16.11M
YoY Change		-41.76%	-313.23%
Interest Expense		$614.0K	$189.0K
YoY Change		224.87%	-73.68%
% of Operating Profit
Other Income/Expense, Net		$1.248M	$1.392M
YoY Change		-10.34%	-23300.0%
Pretax Income		-$8.132M	-$14.71M
YoY Change		-44.73%	-294.95%
Income Tax		-$3.000K	-$603.0K
% Of Pretax Income
Net Earnings		-$8.114M	-$14.07M
YoY Change		-42.34%	-270.74%
Net Earnings / Revenue		-54.21%
Basic Earnings Per Share		-$0.21	-$0.37
Diluted Earnings Per Share		-$0.21	-$0.37
COMMON SHARES
Basic Shares Outstanding	40.23M shares	39.41M shares	38.52M
Diluted Shares Outstanding		39.42M shares	38.53M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.1M	$160.3M
YoY Change	-33.81%	-19.89%
Cash & Equivalents	$106.1M	$160.3M
Short-Term Investments
Other Short-Term Assets	$464.0K	$355.0K
YoY Change	30.7%	173.08%
Inventory
Prepaid Expenses	$7.064M	$4.510M
Receivables	$14.97M	$0.00
Other Receivables	$6.055M	$5.891M
Total Short-Term Assets	$134.7M	$171.1M
YoY Change	-21.28%	-21.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.72M	$12.27M
YoY Change	-12.63%	81.33%
Goodwill	$12.21M	$12.21M
YoY Change	0.0%	-3.33%
Intangibles	$22.74M	$25.90M
YoY Change	-12.21%	-10.88%
Long-Term Investments
YoY Change
Other Assets	$926.0K	$1.055M
YoY Change	-12.23%	24.56%
Total Long-Term Assets	$54.04M	$58.91M
YoY Change	-8.27%	3.6%
TOTAL ASSETS
Total Short-Term Assets	$134.7M	$171.1M
Total Long-Term Assets	$54.04M	$58.91M
Total Assets	$188.7M	$230.0M
YoY Change	-17.95%	-16.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.076M	$5.145M
YoY Change	-40.21%	113.4%
Accrued Expenses	$9.952M	$13.42M
YoY Change	-25.86%	16.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.07M	$18.57M
YoY Change	-18.83%	32.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.406M	$1.278M
YoY Change	10.02%	79.75%
Total Long-Term Liabilities	$1.406M	$1.278M
YoY Change	10.02%	79.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.07M	$18.57M
Total Long-Term Liabilities	$1.406M	$1.278M
Total Liabilities	$29.23M	$34.37M
YoY Change	-14.95%	9.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$217.1M	-$159.3M
YoY Change	36.28%	94.14%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$159.3M	$195.4M
YoY Change
Total Liabilities & Shareholders Equity	$188.7M	$230.0M
YoY Change	-17.95%	-16.52%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$8.114M	-$14.07M
YoY Change	-42.34%	-270.74%
Depreciation, Depletion And Amortization	$700.0K	$700.0K
YoY Change	0.0%	-41.08%
Cash From Operating Activities	-$18.20M	-$11.19M
YoY Change	62.61%	-194.17%
INVESTING ACTIVITIES
Capital Expenditures	$114.0K	$36.00K
YoY Change	216.67%	-101.5%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$114.0K	-$36.00K
YoY Change	216.67%	-98.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	465.0K	46.00K
YoY Change	910.87%
NET CHANGE
Cash From Operating Activities	-18.20M	-11.19M
Cash From Investing Activities	-114.0K	-36.00K
Cash From Financing Activities	465.0K	46.00K
Net Change In Cash	-17.85M	-11.18M
YoY Change	59.62%	-213.33%
FREE CASH FLOW
Cash From Operating Activities	-$18.20M	-$11.19M
Capital Expenditures	$114.0K	$36.00K
Free Cash Flow	-$18.31M	-$11.23M
YoY Change	63.11%	-178.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Entity File Number EntityFileNumber	001-40367
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2255000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-14110000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40228456	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106102000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142090000	usd
	dei	Entity Registrant Name EntityRegistrantName	BARINTHUS BIOTHERAPEUTICS PLC
	dei	Entity Address City Or Town EntityAddressCityOrTown	Harwell, Didcot
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11139000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13420000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	961000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	24559000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16105000	usd
CY2024Q3	us-gaap	Other Operating Income OtherOperatingIncome	210000	usd
CY2023Q3	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9380000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16105000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	631000	usd
CY2023Q3	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	1205000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1248000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8132000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14713000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8114000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14072000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38533833	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38533833	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-14110000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9191000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7820000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1062000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-21930000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1067000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001828185
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Unit 6-10, Zeus Building
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Rutherford Avenue
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	OX11 0DF
	dei	City Area Code CityAreaCode	+44 (0)
	dei	Local Phone Number LocalPhoneNumber	1865 818 808
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	14969000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	usd
CY2024Q3	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	5403000	usd
CY2023Q4	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	4908000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8180000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	134654000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	156905000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	12209000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10719000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11821000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22737000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25108000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7444000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	926000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	882000	usd
CY2024Q3	us-gaap	Assets Assets	188689000	usd
CY2023Q4	us-gaap	Assets Assets	214506000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3076000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1601000	usd
CY2024Q3	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7966000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2024Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	2044000	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1986000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15072000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12598000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10683000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1610000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1823000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1406000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1325000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	457000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	574000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	29228000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27511000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2024Q3	us-gaap	Goodwill Goodwill	12209000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11821000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22737000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25108000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	926000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	882000	usd
CY2024Q3	us-gaap	Assets Assets	188689000	usd
CY2023Q4	us-gaap	Assets Assets	214506000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3076000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1601000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2024Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	2044000	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1986000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15072000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12598000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10683000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1610000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1823000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1406000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1325000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	457000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	574000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	29228000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27511000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39542518	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	39542518	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39542518	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38643540	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391882000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	386602000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217124000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176590000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-15551000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-23315000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	159294000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	186784000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	167000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	159461000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38643540	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391882000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217124000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176590000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-15551000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-23315000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	159294000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	186784000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	167000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	211000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	159461000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	188689000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214506000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14969000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14969000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	802000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15144000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33926000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38501000	usd
	us-gaap	Operating Expenses OperatingExpenses	60541000	usd
	us-gaap	Operating Expenses OperatingExpenses	64728000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	992000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44580000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-63926000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	196000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2041000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2306000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	17000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	41000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	21000	usd
	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	1895000	usd
	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	2921000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	308000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3941000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5514000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58412000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-603000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-47000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-103000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-56054000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39079259	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38320208	shares
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	188689000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214506000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14969000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	802000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33926000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38501000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26615000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26227000	usd
	us-gaap	Operating Expenses OperatingExpenses	60541000	usd
	us-gaap	Operating Expenses OperatingExpenses	64728000	usd
	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44580000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-63926000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2041000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	41000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	21000	usd
CY2024Q3	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	608000	usd
	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	2921000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1392000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3941000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5514000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40639000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58412000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-103000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40534000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38320208	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39079259	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38320208	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7778000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2364000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32814000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-53793000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-5000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-44000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-100000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21882000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32770000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53693000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1615000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	503000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1577000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-15520000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172016000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39079259	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38320208	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7778000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2364000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32814000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-53793000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-48000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-44000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-100000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32770000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1615000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	503000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1577000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-15520000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172016000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1195000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	358000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	164000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156790000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1144000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	465000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9191000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	159461000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2222000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1789000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4580000	usd
CY2023Q1	brns	Shares Cancelled During Period Value Deferred Shares SharesCancelledDuringPeriodValueDeferredShares	0	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-18223000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	233569000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1990000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	123000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5604000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	217462000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7820000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	195603000	usd
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3954000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4269000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4372000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3994000	usd
	brns	Non Cash Lease Expenses NonCashLeaseExpenses	1086000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2022000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1195000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	358000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	164000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-16943000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156790000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1144000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	465000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9191000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	159461000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2222000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4580000	usd
CY2023Q1	brns	Shares Cancelled During Period Value Deferred Shares SharesCancelledDuringPeriodValueDeferredShares	0	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-18223000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	233569000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1990000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	123000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5604000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-23824000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	217462000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7820000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-14110000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	195603000	usd
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3954000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4269000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4372000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3994000	usd
	brns	Non Cash Lease Expenses NonCashLeaseExpenses	1086000	usd
	brns	Non Cash Lease Expenses NonCashLeaseExpenses	787000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-879000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-306000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	86000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	36000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	21000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	14969000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-5800000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2083000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5249000	usd
	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-426000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	417000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1528000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5234000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2044000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1306000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42026000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31322000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-879000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-306000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	86000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	36000	usd
	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	21000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-47000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2254000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	14969000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-5800000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5249000	usd
	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	233000	usd
	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-426000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1358000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	417000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1528000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5234000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2044000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1306000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42026000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5566000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-614000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1926000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	163000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1326000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5326000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1049000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	614000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5566000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-614000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5566000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1326000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1926000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	163000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1326000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1763000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5326000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1049000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35988000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34076000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142090000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194385000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106102000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160309000	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	0	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	287000	usd
	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	0	usd
	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	88000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106100000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35988000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194385000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106102000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160309000	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	0	usd
	brns	Asset Retirement Obligations AssetRetirementObligations	287000	usd
	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106100000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7700000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6600000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6600000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1100000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7700000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6600000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6600000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1100000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-14110000	usd
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-103000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8114000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-14072000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40534000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-56054000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38533833	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39079259	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38320208	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38533833	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39079259	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38320208	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-8129000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-14110000	usd
	us-gaap	Profit Loss ProfitLoss	-40592000	usd
	us-gaap	Profit Loss ProfitLoss	-56157000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-103000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8114000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-56054000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38533833	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39079259	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38320208	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39419447	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38533833	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39079259	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38320208	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7340000	shares
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	600000	usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	5900000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	2000000.0	usd
CY2023Q3	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	1600000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7340000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6391680	shares
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	600000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	2000000.0	usd
CY2023Q3	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	1600000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Current Year FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Year Seven FiniteLivedIntangibleAssetExpectedAmortizationYearSeven	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Year Six FiniteLivedIntangibleAssetExpectedAmortizationYearSix	3200000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Current Year FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Year Seven FiniteLivedIntangibleAssetExpectedAmortizationYearSeven	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3200000	usd
CY2024Q3	brns	Finite Lived Intangible Asset Expected Amortization Year Six FiniteLivedIntangibleAssetExpectedAmortizationYearSix	3200000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7064000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5402000	usd
CY2024Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	652000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	3031000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	464000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7064000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5402000	usd
CY2024Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	652000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	3031000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	464000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1474000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8180000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2024Q3	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	3677000	usd
CY2023Q4	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	4003000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1781000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2412000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	887000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	789000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1037000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	942000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	584000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1066000	usd
CY2024Q3	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7966000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2024Q2	us-gaap	Deferred Income DeferredIncome	839000	usd
CY2023Q2	us-gaap	Deferred Income DeferredIncome	0	usd
CY2023Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	3677000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1781000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	887000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	789000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	584000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1066000	usd
CY2024Q3	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7966000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2024Q2	us-gaap	Deferred Income DeferredIncome	839000	usd
CY2023Q2	us-gaap	Deferred Income DeferredIncome	0	usd
CY2023Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	us-gaap	Deferred Income Addition DeferredIncomeAddition	1360000	usd
CY2023Q3	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	2989000	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
CY2024Q3	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	210000	usd
CY2023Q3	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
CY2024Q3	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	-55000	usd
CY2023Q3	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	-47000	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
CY2024Q3	us-gaap	Deferred Income DeferredIncome	2044000	usd
CY2023Q3	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	us-gaap	Deferred Income DeferredIncome	2044000	usd
CY2023Q3	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q3	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q3	brns	Percentage Of Shares Necessary To Exercise Preemptive Rights PercentageOfSharesNecessaryToExercisePreemptiveRights	0.75
	brns	Period Of Preemptive Rights To Be Exercised PeriodOfPreemptiveRightsToBeExercised	P5Y
CY2023Q4	brns	Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre Emption Rights MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights	1928	gbp
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	us-gaap	Deferred Income Addition DeferredIncomeAddition	1360000	usd
CY2023Q3	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	2989000	usd
	us-gaap	Deferred Income Addition DeferredIncomeAddition	0	usd
CY2024Q3	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	210000	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	992000	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
CY2024Q3	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	-55000	usd
CY2023Q3	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	-47000	usd
	brns	Deferred Income Foreign Exchange Translation Gain Loss DeferredIncomeForeignExchangeTranslationGainLoss	0	usd
CY2024Q3	us-gaap	Deferred Income DeferredIncome	2044000	usd
CY2023Q3	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	us-gaap	Deferred Income DeferredIncome	2044000	usd
CY2023Q3	us-gaap	Deferred Income DeferredIncome	0	usd
CY2024Q3	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q3	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2024Q3	brns	Percentage Of Shares Necessary To Exercise Preemptive Rights PercentageOfSharesNecessaryToExercisePreemptiveRights	0.75
	brns	Period Of Preemptive Rights To Be Exercised PeriodOfPreemptiveRightsToBeExercised	P5Y
CY2023Q4	brns	Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre Emption Rights MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights	1928	gbp
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1953422	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2221706	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	658512	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	664449	shares
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1953422	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2221706	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	658512	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	664449	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7340000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.03
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6391680	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.86
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4000000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1144000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3954000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4269000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7444000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7340000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.03
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6391680	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.86
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4000000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1144000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3954000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4269000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7444000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1986000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10683000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1306000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	396000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M8D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	189000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	369000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	192000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1086000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	787000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	369000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1986000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10683000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1306000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	396000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M8D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	189000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	369000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	192000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1086000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	787000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	369000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	192000	usd
	us-gaap	Lease Cost LeaseCost	1086000	usd
	us-gaap	Lease Cost LeaseCost	976000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	496000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1994000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2018000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2043000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2068000	usd
CY2024Q3	brns	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	8153000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16772000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4103000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	12669000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	us-gaap	Lease Cost LeaseCost	192000	usd
	us-gaap	Lease Cost LeaseCost	1086000	usd
	us-gaap	Lease Cost LeaseCost	976000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	496000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1994000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2018000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2043000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2068000	usd
CY2024Q3	brns	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	8153000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16772000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4103000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	12669000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001828185-24-000085-index-headers.html	Edgar Link	pending
0001828185-24-000085-index.html	Edgar Link	pending
0001828185-24-000085.txt	Edgar Link	pending
0001828185-24-000085-xbrl.zip	Edgar Link	pending
brns-20240930.htm	Edgar Link	pending
brns-20240930.xsd	Edgar Link	pending
brns-20240930xexx311.htm	Edgar Link	pending
brns-20240930xexx312.htm	Edgar Link	pending
brns-20240930xexx321.htm	Edgar Link	pending
brns-20240930_g1.jpg	Edgar Link	pending
brns-20240930_cal.xml	Edgar Link	unprocessable
brns-20240930_def.xml	Edgar Link	unprocessable
brns-20240930_lab.xml	Edgar Link	unprocessable
brns-20240930_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
leonhooftman-executiveserv.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
brns-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRNS
Barinthus Biotherapeutics PLC Stock $brns

2024 Q4 Form 10-Q Financial Statement

#000182818524000085 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS Barinthus Biotherapeutics PLC Stock $brns

2024 Q4 Form 10-Q Financial Statement

#000182818524000085 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS
Barinthus Biotherapeutics PLC Stock $brns